NEUP vs. AKTX, COEP, LVTX, MAAQ, FGEN, CVKD, MRNS, DYAI, INKT, and ALLK
Should you be buying Neuphoria Therapeutics Inc. - Common Stock stock or one of its competitors? The main competitors of Neuphoria Therapeutics Inc. - Common Stock include Akari Therapeutics (AKTX), Coeptis Therapeutics (COEP), LAVA Therapeutics (LVTX), Mana Capital Acquisition (MAAQ), FibroGen (FGEN), Cadrenal Therapeutics (CVKD), Marinus Pharmaceuticals (MRNS), Dyadic International (DYAI), MiNK Therapeutics (INKT), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry.
Neuphoria Therapeutics Inc. - Common Stock vs.
Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
Akari Therapeutics has lower revenue, but higher earnings than Neuphoria Therapeutics Inc. - Common Stock.
15.9% of Neuphoria Therapeutics Inc. - Common Stock shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 0.7% of Neuphoria Therapeutics Inc. - Common Stock shares are held by company insiders. Comparatively, 38.9% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Akari Therapeutics received 261 more outperform votes than Neuphoria Therapeutics Inc. - Common Stock when rated by MarketBeat users. However, 100.00% of users gave Neuphoria Therapeutics Inc. - Common Stock an outperform vote while only 49.53% of users gave Akari Therapeutics an outperform vote.
Neuphoria Therapeutics Inc. - Common Stock currently has a consensus target price of $21.00, suggesting a potential upside of 279.75%. Given Neuphoria Therapeutics Inc. - Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics Inc. - Common Stock is more favorable than Akari Therapeutics.
In the previous week, Neuphoria Therapeutics Inc. - Common Stock and Neuphoria Therapeutics Inc. - Common Stock both had 3 articles in the media. Neuphoria Therapeutics Inc. - Common Stock's average media sentiment score of 0.75 beat Akari Therapeutics' score of -0.48 indicating that Neuphoria Therapeutics Inc. - Common Stock is being referred to more favorably in the media.
Neuphoria Therapeutics Inc. - Common Stock has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.
Summary
Neuphoria Therapeutics Inc. - Common Stock beats Akari Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Neuphoria Therapeutics Inc. - Common Stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuphoria Therapeutics Inc. - Common Stock Competitors List
Related Companies and Tools
This page (NASDAQ:NEUP) was last updated on 5/22/2025 by MarketBeat.com Staff
